AMP v. USPTO | GenomeWeb

AMP v. USPTO

By Turna Ray
The American Civil Liberties Union and the Public Patent Foundation have decided to ask the Supreme Court to take up their case challenging Myriad Genetics' patents on the BRCA 1 and BRCA 2 genes.

Adding large gene rearrangement analysis to Myriad's Comprehensive BRACAnalysis test could detect variants associated with increased risk for hereditary breast and ovarian cancer that occur more frequently in some populations and would otherwise be missed.

The higher court will consider whether two method patents held by Prometheus Laboratories claim natural phenomena and are therefore not patentable under the law.

Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.